CABAZITAXEL

Growth

cabazitaxel

NDAINTRAVENOUSSOLUTION
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.

Clinical Trials (5)

NCT06691984Phase 3Recruiting

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Started Dec 2024
675 enrolled
Metastatic Castration-resistant Prostate Cancer
NCT04592237Phase 2Active Not Recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Started Dec 2020
120 enrolled
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
NCT04495179Phase 2Completed

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Started Aug 2020
30 enrolled
Progressive Metastatic Castrate-Resistant Prostate Cancer
NCT03764540Phase 2Terminated

Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide

Started Apr 2019
57 enrolled
Metastatic Prostate Cancer
NCT02844582Phase 2Terminated

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Started Dec 2017
2 enrolled
Hormone-Resistant Prostate CancerStage IV Prostate Adenocarcinoma